PPARA and cancer: On the other hand, fenofibrate, which is a PPARα agonist (i.e., activates PPARα), is used for hypercholesterolemia, and was reported to inhibit cancer cell proliferation by increasing β-oxidation and inhibiting glycolysis [42,43].